Clinical Trial Search

Primary: MTD of Afatinib in Combination With Trastuzumab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib). — 20 mg

Primary: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 38.975; 39.250; 61.866; 71.949 nanogram per milliliter (ng/mL)

Primary: Number of Grade 3 or Higher Adverse Events — 0 Events

Primary: Area Under the Concentration-time Curve of MK-0822 From Time 0 to Infinity (AUC0-∞) After Single Dose — 28.84; 33.79 μM*hr

Primary: Maximum Observed Plasma Concentration (Cmax) - Chlorpromazine — 2671; 2720 pg/mL

Primary: Maximum Observed Plasma Concentration (Cmax) — 14.1; 14.9 ng/mL

Primary: Change From Baseline in Markers of Cardiac Collagen Turnover (PINP) in Patients With Systolic Heart Failure and Compared With Healthy Controls. — 48.1; 48.1; 39 ng/ml…

Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants

Primary: Dose Limiting Toxicity — 0; 0 participants with DLTs

Primary: Occurrence of Solicited Symptoms During a 8 Day Follow-up Period After Each Vaccination — 24; 11; 35; 15 events

Primary: Number of Participants Experiencing Adverse Events — 22 Participants

Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants

Primary: AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) — 600; 714…

Primary: Pharmacokinetic Parameter Cmax of Ticagrelor — 560.32; 598.35; 370.76 ng/mL